Aptamers News and Research

RSS

Exploring receptor-blocking conserved non-neutralizing antibodies for SARS-CoV-2 therapy

In a new study, researchers hypothesized and developed broad-spectrum SARS-CoV-2 inhibitors, ReconnAbs, by modifying the existing non-neutralizing antibodies targeted towards the highly conserved epitopes of the SARS-CoV-2 spike (S) protein combined with a receptor-blocking component.

28 Jan 2022

Rapid, highly accurate drug detection vital to reducing the adverse impacts of addiction

Rapid, accessible and highly accurate detection of addictive substances such as opiates and cocaine is vital to reducing the adverse personal and societal impacts of addiction, something current drug detection systems can take too long to provide.

22 Jan 2022

Applications of bioconjugated nanomaterials in SARS-CoV-2 diagnostics

In this study, the researchers not only elucidate the recent bioconjugated nanomaterials for targeted diagnosis of SARS-CoV-2, but they also provide the rationale behind these developments by discussing the mechanisms and approaches.

18 Jan 2022

AI-driven solution predicts RNA and DNA binding sites to accelerate rational drug discovery

The iMolecule group from Skoltech has developed an artificial intelligence-driven solution that uses data on the structure of RNA or DNA molecules to identify sites on them where interaction with potential drug candidates can occur.

11 Jan 2022

Scientists develop first photo-electrochemical aptasensor to detect SARS-CoV-2 virus in saliva

Scientists at the Universidad Carlos III de Madrid (UC3M) have developed the first photo-electrochemical aptasensor that detects the SARS-CoV-2 virus in a saliva sample.

20 Dec 2021

Equipment-free handheld microfluidic injection provides visible readout of SARS-CoV-2 detection

In this paper, a group of researchers from Harvard Medical School, McGill University, and Tianjin University describes an on-chip diagnostic technology for the direct detection of SARS-CoV-2 N protein in nasal samples that combines the advantages of hydrodynamic microfluidic filtration and sandwich immunoassay.

5 Dec 2021

Studying influenza A virus and peptide interactions with electrically controllable DNA nanoconstructs

German scientists used DNA nanolevers to target the interaction between a peptide known as PeB and influenza A.

3 Nov 2021

Novel proteomics approach predicts severe COVID-19 outcomes

Researchers in the United States, Canada, and the UK have developed a potential new approach to predicting severe and critical outcomes among patients with coronavirus disease 2019 (COVID-19).

6 Oct 2021

DNA sensor can detect infectious viruses in minutes

A new sensor can detect not only whether a virus is present, but whether it's infectious – an important distinction for containing viral spread.

23 Sep 2021

Aptamers for Targeting SARS-CoV-2 Proteins

AMSBIO has further expanded its product range to help in the fight against COVID-19 with the introduction of a new range of aptamers targeting SARS-CoV-2 proteins to aid development of new kits and assays.

From AMS Biotechnology 15 Sep 2021

SARS-CoV-2 detection by machine learning surface-enhanced Raman spectroscopy

Surface-enhanced Raman spectroscopy is a highly sensitive molecule characterization method, significantly more sensitive than ordinary Raman spectroscopy due to the excitation of Raman modes matching the plasmon resonance frequency of the surface metal utilized, usually gold, silver, or copper.

11 Aug 2021

Emerging biosensing technologies could revolutionize the diagnosis of neonatal sepsis

Sepsis in newborn infants can be fatal. Early diagnosis is thus key to effectively manage the infection. Conventional diagnostic methods are, however, time-consuming.

11 Aug 2021

Neutralizing aptamers block SARS-CoV-2 infection in vitro

A new study describes the clinical utility of aptamers against SARS-CoV-2.

13 Jul 2021

Novel molecule could offer a new way to fight against SARS coronavirus 2

Scientists at the University of Bonn and the caesar research center have isolated a molecule that might open new avenues in the fight against SARS coronavirus 2. The active ingredient binds to the spike protein that the virus uses to dock to the cells it infects.

27 Mar 2021

Aptamer Group and Mologic enter commercial partnership to develop aptamer-based SARS-CoV-2 rapid antigen test

Aptamer Group, the developer of diagnostic and therapeutic Optimer™ reagents, today announced a commercial partnership with Mologic.

From Aptamer Group 18 Mar 2021

Quantum dot-based affinity biosensors in microfluidic systems offer an alternative SARS-CoV-2 diagnostics platform

In a new study published in Emergent Materials, researchers show how microfluidic systems integrated with quantum dot-based affinity biosensors can serve as a valuable platform to rapidly and accurately diagnose SARS-CoV-2 infection.

17 Mar 2021

Aptamer Group Extends Collaboration With Leading Biopharmaceutical Company to Explore Next-Generation Drug Delivery Approaches

Aptamer Group, the developer of Optimer™ reagents and therapeutics, today announced the extension of their current agreement with AstraZeneca, a global biopharmaceutical company. Image credit: Shutterstock.com/Billion Photos

From Aptamer Group 5 Mar 2021

Small wearable sensor can detect stress biomarker in sweat

We've all felt stressed at some point, whether in our personal or professional lives or in response to exceptional circumstances like the COVID-19 pandemic. But until now there has been no way to quantify stress levels in an objective manner.

6 Feb 2021

New SERS-based sensor can detect influenza A viral pathogens with high reproducibility

Respiratory diseases like influenza can spread rapidly and escalate to global health crises. Thus, to control them, simple yet sensitive detection techniques are needed. Surface-enhanced Raman scattering (SERS) is a potential candidate but currently lacks reproducibility.

22 Jan 2021

Pioneering diagnostics platform changes the way COVID-19 is detected

Montreal-based Two-Photon Research Inc. announces CAST, a diagnostics platform that changes the way viruses are detected. The CAST platform uses TPR’s patented Aptamer Molecular Photonic Beacon™ that photonically interfaces with smartphones.

10 Dec 2020